増強剤を再プログラムして転移を促す
Raul Mostoslavsky1, Nabeel Bardeesy2
1The Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA; Massachusetts General Hospital Center for Regenerative Medicine, Harvard Medical School, Boston, MA 02114, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.
Cell
|August 26, 2017
まとめ
Foxa1による大規模な増強剤再プログラムが伴う. この転写因子は 早期の内皮幹細胞プログラムを活性化し 腫瘍細胞の拡散を促します
科学分野:
- 腫瘍学
- 分子生物学
- 遺伝学
背景:
- 原発性腫瘍の得られた分子変異は 転移過程を誘導する可能性があります
- 癌細胞の転移は 遺伝的・表遺伝的変化を含む 複雑なプロセスです
研究 の 目的:
- 臓がんの転移の原因となる 分子機構を調査する
- 癌細胞の拡散に関与する重要な転写因子と制御経路を特定する.
主な方法:
- 臓がんにおける増強剤再プログラミングの分析
- 転写因子Foxa1の役割を調査する.
- 分子解析を用いた活性化トランスクリプションプログラムを特定する.
主要な成果:
- ロエと仲間たち 転移した臓がんは 大規模な増強剤の再プログラムを示しています
- 転写因子Foxa1は,この再プログラムプロセスにおいて重要な役割を果たします.
- 初期の内皮幹細胞の転写プログラムにおけるFoxa1の活性化が確認された.
結論:
- Foxa1によるエンハンサー再プログラムが 臓がんの転移の主要な要因である.
- Foxa1または内皮幹細胞プログラムをターゲットにすることで,臓がんの治療戦略を提供することができます.
関連する概念動画
02:30Metastasis
6.7K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
6.7K
02:53Adaptive Mechanisms in Cancer Cells
7.2K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.2K
01:29Somatic to iPS Cell Reprogramming
2.7K
Reprogramming alters the gene expression in somatic cells, transforming them into induced pluripotent stem (iPS) cells over several generations. Scientists can reprogram cells by introducing genes for four transcription factors—Oct4, Sox2, Klf4, and c-Myc (OSKM) by viral or non-viral methods. These factors are also known as Yamanaka factors after Shinya Yamanaka, who first generated iPS cells using mouse skin cells. Yamanaka was awarded the Nobel Prize in Physiology or Medicine in 2012...
2.7K
02:38Mitogens and the Cell Cycle
8.2K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.2K